Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Checked against the public recordLast updated Apr 22, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Drug: Glesatinib; Drug: Sitravatinib; Drug: Mocetinostat; Drug: Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of non-small cell lung cancer. * Prior treatment with a checkpoint inhibitor (as appropriate per cohort) * Adequate bone marrow and organ function Exclusion Criteria: * Uncontrolled tumor in the brain * Unacceptable toxicity with prior checkpoint inhibitor * Impaired heart function
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Yuma Regional Medical CenterYuma, Arizona
- Beverly Hills Cancer CenterBeverly Hills, California
- City of Hope National Medical CenterDuarte, California
- University of California San DiegoLa Jolla, California
- University of California San Francisco Comprehensive Cancer CenterSan Francisco, California
- University of California Los Angeles - Torrance - Community Cancer CareSanta Clarita, California
- Rocky Mountain Cancer Centers - Denver - MidtownDenver, Colorado
- Baptist HealthLouisville, Kentucky
- Henry Ford HospitalDetroit, Michigan
- Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
- University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
- Saint Francis Cancer Treatment CenterGrand Island, Nebraska
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 22, 2024. Always confirm current availability with the study team.